Page 2 - Les meilleurs doctors traitant la maladie suivante : Chordome - TOP -54 des médecins

Le Dr Yildiz a beaucoup publié sur les maladies endocriniennes et oncologiques rares, en mettant l'accent sur les tumeurs neuroendocrines et les syndromes paranéoplasiques.

• Plus de 15 ans d'expérience en oncologie médicale
• Spécialisation dans les tumeurs neuroendocrines et les pathologies cancéreuses complexes
• Publication de plus de 17 articles évalués par des pairs dans des revues internationales
• Exercice au Medipol Mega University Hospital

Dirige le département des lésions osseuses métastatiques du centre médical Ichilov, se concentrant particulièrement sur les cancers osseux complexes comme le chordome.

• Chirurgien orthopédiste spécialisé en orthopédie oncologique
• Professeur à la faculté de médecine de l'université de Tel Aviv
• Formé à l'Université hébraïque de Jérusalem
• Effectuer des stages cliniques aux États-Unis
• Médecin senior dans un centre d'orthopédie oncologique en Israël

Le professeur associé Dr Yusuf Acikgoz apporte son expertise internationale de l'Université d'État de l'Ohio à l'hôpital universitaire Lokman Hekim d'Ankara.

• Se spécialiser en oncologie médicale avec un accent sur les essais cliniques
• Participer à des études de phase III telles que CheckMate-649 et Fortitude-101
• Membre de l'American Society of Clinical Oncology (ASCO)
• Certifié en Bonnes Pratiques Cliniques et en Protection des Sujets Humains

Le Dr Alemdar est spécialisé en oncologie médicale au complexe hospitalier Medical Park Antalya, avec une formation approfondie en médecine interne et en oncologie.

• Certifié en oncologie médicale depuis 2018
• Plus de 15 ans d'expérience médicale dans divers hôpitaux
• Formation spécialisée à la faculté de médecine de l'université Akdeniz
• Travailler avec une approche multidisciplinaire pour des soins complets contre le cancer

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Le Dr Nail Paksoy apporte une expertise spécialisée en oncologie, se concentrant sur les cas complexes à l'hôpital Medipol Bahçelievler.

• Certifié en oncologie médicale par l'ESMO
• Publier de nombreuses études sur les cancers rares et les traitements innovants
• Participer activement à des essais cliniques internationaux en oncologie
• Professeur associé à l'Université Medipol d'Istanbul

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Plus de 30 ans d'expérience spécialisée en virothérapie – l'un des domaines les plus récents de l'immunologie – à la Clinique Pallas.

• Chef du Centre d'immunologie clinique de l'Hôpital universitaire clinique Pauls Stradins
• Diplômé de l'Institut médical de Riga avec un internat en médecine interne
• Expert en traitements immunologiques pouvant être adaptés à des pathologies spécifiques

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Le Dr Topcu apporte son expertise internationale du MD Anderson et du Sunnybrook Odette Cancer Center à l'hôpital universitaire Biruni.

• Se spécialiser dans les cancers rares, notamment le chordome et les sarcomes
• Membre de l'ESMO et de l'ASCO – standards mondiaux en oncologie
• Formation dans des institutions de premier plan aux États-Unis, au Canada et en Turquie
• Travailler sur de multiples types de cancers avec des cas complexes

Spécialisé en radio-oncologie avec une formation de l'Université de Marmara, réputée pour son programme médical rigoureux.

• Formé au département de radio-oncologie de l'Université de Marmara
• Études de médecine de premier cycle terminées à l'Université de Marmara
• La formation comprend une expérience internationale en Azerbaïdjan

Le professeur associé Dr Emrah Eraslan est spécialisé en oncologie et possède une vaste expérience dans le traitement de divers cancers, y compris des cas rares comme le chordome, à l'hôpital Koru Ankara.

• Certifié en oncologie médicale avec plus de 12 ans d'expérience
• Spécialisé dans les cancers du sein, de la prostate, du poumon et colorectal
• Contribution à la recherche en oncologie avec de nombreuses publications
• Formé dans des institutions prestigieuses, notamment l'Université d'Ankara et l'Hôpital d'enseignement et de recherche en oncologie Dr Abdurrahman Yurtaslan d'Ankara